Efficacy of gefitinib at reduced dose in EGFR mutant non-small cell lung carcinoma-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Efficacy of gefitinib at reduced dose in EGFR mutant non-small cell lung carcinoma

Published:2019-11 Issue:10 Volume:30 Page:1048-1051
ISSN:0959-4973
Container-title:Anti-Cancer Drugs
language:en
Short-container-title:

Author:

Kwok Wang Chun,Ho James Chung Man,Tam Terence Chi Chun,Lui Macy Mei Sze,Ip Mary Sau Man,Lam David Chi Leung

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Cancer Research,Pharmacology (medical),Pharmacology,Oncology

Reference11 articles.

1. Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in asia (IPASS).;Fukuoka;J Clin Oncol,2011

2. Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin-paclitaxel for chemo-naïve non-small cell lung cancer with sensitive EGFR gene mutations (NEJ002).;Inoue;Ann Oncol,2013

3. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial.;Mitsudomi;Lancet Oncol,2010

4. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma.;Mok;N Engl J Med,2009

5. The dissociation of gefitinib trough concentration and clinical outcome in NSCLC patients with EGFR sensitive mutations.;Xin;Sci Rep,2015

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Serum protein level as a predictor of therapeutic response and adverse effects associated with afatinib use;Journal of Thoracic Disease;2022-06

2. Optimized Dosing: The Next Step in Precision Medicine in Non-Small-Cell Lung Cancer;Drugs;2021-12-11

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3